The patient was enrolled on a tumor sequencing protocol (ClinicalTrials.gov identifier: NCT02688517), and comprehensive genomic profiling analysis revealed the presence of BRAF-V600E mutation, TP53-G245S, SMAD4-S504R, and PTEN loss (Fig 2). This evidence concerns the gene SMAD4 and neoplasm.